# EDGAR Filing Document

**Accession Number:** 0001840199
**File Stem:** 0001840199-26-000011
**Filing Date:** 2026-3
**Character Count:** 4278
**Document Hash:** e4db081f889240a432536329970ac9cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001840199-26-000011.hdr.sgml**: 20260311

**ACCESSION NUMBER**: 0001840199-26-000011

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260311

**DATE AS OF CHANGE**: 20260311

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Waldencast plc
- **CENTRAL INDEX KEY:** 0001840199
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40207
- **FILM NUMBER:** 26743562

**BUSINESS ADDRESS:**
- **STREET 1:** 81 FULHAM ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW3 6RD
- **BUSINESS PHONE:** 44 (0)20 3196 0264

**MAIL ADDRESS:**
- **STREET 1:** 81 FULHAM ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW3 6RD

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Waldencast Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210112

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 or 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of: March 2026

Commission File Number: 001-40207

**Waldencast plc**

(Translation of Registrant's name into English)

**81 Fulham Road**

**London, SW3 6RD**

**United Kingdom**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

------

**Information in this Report**

The information in this report on Form 6-K ("Report") shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date**

**March 11, 2026 – London, United Kingdom –** Waldencast plc, (NASDAQ: WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review.

**About Waldencast plc**

Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing its vision was the business combination with Obagi Medical and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/.

**Contacts**

**Investors**

ICR

Allison Malkin

waldencastir@icrinc.com

**Media**

ICR

Brittany Fraser

Waldencast@icrinc.com

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | Waldencast plc | Waldencast plc |
| | | (Registrant) | (Registrant) |
| Date: March 11, 2026 | By: | /s/ Manuel Manfredi | /s/ Manuel Manfredi |
|  |  | Name: | Manuel Manfredi |
|  |  | Title: | Chief Financial Officer and Principal Financial Officer |

---

<br>